Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Investor Presentation (September 2020)
54 slides from Therapeuticsmd's investor presentation, Sep 14, 2020
Slide 1: Corporate Presentation
Corporate Presentation September 14, 2020 FOR INVESTOR PRESENTATION PURPOSES ONLY.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as “we,” “our,” or “the Company”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statemen
Slide 3: Recent Updates
Recent Updates § Expanded patent protection for ANNOVERA with two Orange Book eligible patents § U.S. Patent No. 10,765,628 issued on September 8, 2020 and U.S. Patent No. 10,780,047 is scheduled to be issued on September 22, 2020 § Our flagship product, ANNOVERA, reached record high in July with ~1
Slide 4: FOR INVESTOR PRESENTATION PURPOSES ONLY.
FOR INVESTOR PRESENTATION PURPOSES ONLY. 4
Slide 5: ANNOVERA Market Opportunity
ANNOVERA Market Opportunity ANNOVERA is differentiated as it is patient- % of Women using prescription controlled, procedure-free and long-lasting contraception by method 18.8 Million women* Ring Patch Injectable 4% 1% 8% Patient- controlled ü ü Implant 9% Oral Contraceptive Procedure- 48% free ü ü
Slide 6: Key Performance Metrics: ANNOVERA
Key Performance Metrics: ANNOVERA ANNOVERA Monthly TRx 2Q 2020 2000 1900 TRx to patients ~2,400 # Prescribers w/ TRx ~1,100 1700 1530 Adjudication rate ~99% 1400 1170 73% § Projected August TRx ~1,900 1100 growth § 2Q20 TRx of ~2,400 8 weeks vs 800 previous 8 § Vast majority of patients paying $0 co
Slide 7: 2020 Commercial Priorities
2020 Commercial Priorities Prescriber Consumer Channel Drive depth and breadth of Accelerate performance prescribing for ANNOVERA trajectory through consumer ANNOVERA acceleration and IMVEXXY in “Hybrid” campaign Launches for across multiple channels ANNOVERA and IMVEXXY Reality § Salesforce retrain
Slide 8: Top Partners in Key Channels
Top Partners in Key Channels TXMD Sales Force ~135 Reps and Managers Delivering our Current ANNOVERA Volume 18.8M women on birth control annually Medicaid market US Military market Telemedicine Platforms MBG- Puerto Rico ~15% of all ~3% of all Large/Growing Segment ~$200M in total contraceptive sale
Slide 9: Focused on delivering resources and access to the public health sector
Focused on delivering resources and access to the public health sector FOR INVESTOR PRESENTATION PURPOSES ONLY. 9
Slide 10: Afaxys Overview – Significant Public Health and Contraceptive Experience
Afaxys Overview – Significant Public Health and Contraceptive Experience § #1 Provider of oral & emergency contraceptives to U.S. Public Health and University clinics § 10+ Years of providing reliable and affordable access to contraception § 8,000 Clinics and other public healthcare providers servic
Slide 11: Afaxys Highlights
Afaxys Highlights Afaxys will be launching ANNOVERA into the Medicaid market: ~15% of the overall birth control market § Medicaid market represents a significant revenue opportunity with ~15% of the Medicaid overall birth control market § 36 States cover ANNOVERA with Unrestricted Medicaid Fee for S
Slide 12: Department of Defense: WSI
Department of Defense: WSI, a pharmaceutical company focused on serving women in the public health system FOR INVESTOR PRESENTATION PURPOSES ONLY. 12
Slide 13: WSI: A Leader in Contraceptive Sales in the Military
WSI: A Leader in Contraceptive Sales in the Military WSI has significant experience working in the Federal Government Healthcare Systems WSI Previously launched NuvaRing into the military 92 Military bases § Our goal is to have ANNOVERA in all major military treatment facilities that provide contrac
Slide 14: Why is ANNOVERA a Unique Solution for the Military?
Why is ANNOVERA a Unique Solution for the Military? § Women in the Military are actively on missions in the United States and across the world § Taking a daily pill while out in the field is not easy to do or remember § ANNOVERA, with one ring in a small case, is easy to utilize wherever these women
Slide 15: Telehealth Channel
Telehealth Channel FOR INVESTOR PRESENTATION PURPOSES ONLY. 15
Slide 16: Six Birth Control Telehealth Providers Live
Six Birth Control Telehealth Providers Live § Emerging digital marketing and e-commerce platforms reaching millions of women each year § Over 75,000 units of NuvaRing dispensed in 2019 ANNOVERA is included on 6 telehealth platforms: FOR INVESTOR PRESENTATION PURPOSES ONLY. 16
Slide 17: ANNOVERA: a Unique Solution for the Online Birth Control Market
ANNOVERA: a Unique Solution for the Online Birth Control Market • Long-lasting contraceptive market net revenue has been growing at ~15% 7-year CAGR%* • The telemedicine channel for birth control has been accelerating quickly, but until now had no opportunity to enter the long-lasting market. • ANNO
Slide 18: Prescriber Interest in ANNOVERA Coupled with a Positive Patient Experience will Drive Continued Growth
Prescriber Interest in ANNOVERA Coupled with a Positive Patient Experience will Drive Continued Growth HCPs PATIENTS Early feedback from Healthcare 1,036 women: Phase 3 acceptability study Practitioners on ANNOVERA’s value proposition has been positive** § After 1 year of use: 75% § HCPs aware of AN
Slide 19: Importance of Consumer Awareness and Education
Importance of Consumer Awareness and Education § Majority of women know the birth control method they want before seeing their Healthcare Professional § Market is moving to long-lasting contraceptives at a ~15% 7-year CAGR1 § ~47% patients rejected IUDs/Implants due to not wanting a procedure2 § ANN
Slide 20: Planned Investment in ANNOVERA Consumer Marketing Remainder of Year
Planned Investment in ANNOVERA Consumer Marketing Remainder of Year POPSUGAR Media PR Campaign & Consumer Launch Influencers Campaign Celebrity Spokesperson JULY SEPTEMBER OCTOBER Q4 FOR INVESTOR PRESENTATION PURPOSES ONLY. 20
Slide 21: POPSUGAR Overview – Highly Relevant Content on a Massive Platform
POPSUGAR Overview – Highly Relevant Content on a Massive Platform Our Objective This program is designed to increase reach and awareness for ANNOVERA POPSUGAR reaches & engages our audience § #1 female lifestyle brand § 300M readers every month § 1 in 2 Millennials (22-38 years old) § 33M social fol
Slide 22: POPSUGAR Supporting Media Snapshot (currently live)
POPSUGAR Supporting Media Snapshot (currently live) POPSUGAR Homepage Takeover POPSUGAR Display Banners FOR INVESTOR PRESENTATION PURPOSES ONLY. 22
Slide 23: Influencer Program to Reach Target Audience
Influencer Program to Reach Target Audience Objective Work with influencers who have a strong presence with our target audiences to build content that increases awareness of ANNOVERA, showcases its benefits and convinces women to EXAMPLE trade up to a better birth-control ANNOVERA Receives - 22 infl
Slide 24: Influencer Program Structure– Launching in October
Influencer Program Structure– Launching in October Reach Type of # of (~# of Followers influencer influencers per Influencer) Network of Online Web Celeb 1 2.5MM+ • Product Overview Influencers • Key Messages Macro Creator 4 200K+ • Target Demos Mid-Tier 5 80K+ Content Types per influencer Micro Cre
Slide 25: Expectations for a Successful Brand
Expectations for a Successful Brand Contraception ANNOVERA Revenue Time to Achieve Market Size 4-5% Market Share at Different Example Market Shares $5 billion 1%: 180K Rx, ~$360M market size 2%: 360K Rx, ~$720M Lo-Loestrin ~4 years 28 million new 3%: 540K Rx, ~$1.1B prescriptions 4%: 720K Rx, ~$1.4B
Slide 26: FOR INVESTOR PRESENTATION PURPOSES ONLY.
FOR INVESTOR PRESENTATION PURPOSES ONLY. 26
Slide 27: IMVEXXY is “Redefining Relief”
IMVEXXY is “Redefining Relief” § Indicated for moderate to severe dyspareunia, a symptom of VVA, due to menopause § Small, digitally inserted, softgel vaginal insert that dissolves completely § Easy to use without the need for an applicator § Mess-free administration § Use any-time of day § Lowest a
Slide 28: Key Performance Metrics: IMVEXXY
Key Performance Metrics: IMVEXXY IMVEXXY Weekly NRx 2Q 2020 TRx to patients ~118,000 3 # Prescribers w/ TRx ~12,000 Overall adjudication rate ~44% 2.5 § Focus on fills allows for continued revenue growth Thousands 2 § Average of 5 fills per patient since launch 22% growth § Market decline 3% year ov
Slide 29: COVID-19 Impact on the Menopause Market
COVID-19 Impact on the Menopause Market The VVA market has decreased in volume we believe due to COVID-191,2,3 § GYN visits for less serious events like VVA are down due to COVID-19, negatively impacting IMVEXXY and the volume for the VVA class of drugs § Commercial insurance receding due to job los
Slide 30: Continue to Optimize Net Revenue for IMVEXXY and BIJUVA
Continue to Optimize Net Revenue for IMVEXXY and BIJUVA Having achieved broad payor coverage, TXMD to begin normalize patience assistant programs with the goal of increasing net revenue per script Gross Revenue to Net Revenue Levers to Increase Net Revenue per Unit Gross Revenue 11. Increase average
Slide 31: IMVEXXY DTC Campaign Motivates Women to Take Action
Women Drive the Discussion and Initiations. IMVEXXY DTC Campaign Motivates Women to Take Action Across Multiple Channels Website Social Ads Online Video Player Display Ads Social Display Rx Edge – In Aisle Search FOR INVESTOR PRESENTATION PURPOSES ONLY. 31
Slide 32: FOR INVESTOR PRESENTATION PURPOSES ONLY.
FOR INVESTOR PRESENTATION PURPOSES ONLY. 32
Slide 33: Key Performance Metrics: BIJUVA
Key Performance Metrics: BIJUVA BIJUVA Monthly TRx Maintain Brand Loyalists • Targeted approach with team also 12 supporting Bio-Ignite 11 10.84 Thousands 2Q 2020 10 ~27,600 9.62 TRx to patients 9.3 9.11 9.19 8.92 9 # Prescribers w/ TRx ~4,200 8.43 Overall adjudication rate ~56% 8 JAN FEB MAR APR MA
Slide 34: Regulation of the Compounding Industry
Regulation of the Compounding Industry National Academies of Science, Engineering and Medicine (NASEM) • Report commissioned by FDA and published on July 1, 2020 looking at bio- identical compounding industry • NASEM recommendations for stronger regulation and discipline around promotion and dispens
Slide 35: Appendix
Appendix FOR INVESTOR PRESENTATION PURPOSES ONLY. 35
Slide 36: 2Q20 Key Metrics
2Q20 Key Metrics ANNOVERA IMVEXXY BIJUVA Net Revenue ~$1.8M ~$5.1M ~$1.4M Average Net Revenue / Unit: ~$1,3321 ~$412 ~$452 Overall adjudication rate: ~99% ~44% ~56% 1 Average net revenue per unit calculated based on units sold to wholesalers and pharmacies divided into net revenue for the quarter 2
Slide 37: A pharmacy that provides a modernized consumer experience for prescription fulfillment
A pharmacy that provides a modernized consumer experience for prescription fulfillment FOR INVESTOR PRESENTATION PURPOSES ONLY. 37 Confidential
Slide 38: vitaCare - History
vitaCare - History § vitaCare Prescription Services, Inc. is a wholly-owned subsidiary of TherapeuticsMD, Inc. § TXMD leverages vitaCare to help meet the needs of its patients and prescribers, and ensure continued availability of products to patients § The vitaCare patient model assists patients in
Slide 39: A Pharmacy that Provides a Modernized Consumer Experience for Prescription Fulfillment
A Pharmacy that Provides a Modernized Consumer Experience for Prescription Fulfillment The traditional pharmacy experience is broken. Patients wait in line without knowing if the product is available or what price they will pay Price transparency and Solves payor hurdles Product delivery to door or
Slide 40: Traditional Prescription Fill Experience
Traditional Prescription Fill Experience Prescription drugs – the only industry in the US where you have no idea how much your prescription will cost, if it’s in stock, or what other documentation might be needed to get it. Complicated Process 1 Doctor writes script and 2 Patient goes tos pharmacy 3
Slide 41: vitaCare: A New Simple Process
vitaCare: A New Simple Process Simple Process 1 Doctor writes script 2 vitaCare Pharmacy Tech contacts patient, 3 Patient goes to pharmacy and and sends to vitaCare explains cost and fill options based on picks up prescription or via EMR patient’s insurance receives via mail order § Patient chooses
Slide 42: Empowers manufacturers to manage their product with precision
Empowers manufacturers to manage their product with precision that reaches each script received Manufacturers can now manage their business at the pharmacy transaction level. Real-time pharmacy transaction and business intelligence data is now available to the manufacturer. Manufacturers now have ac
Slide 43: vitaCare – Key Concepts
vitaCare – Key Concepts § vitaCare is a licensed pharmacy that acts as a datahub (does not adjudicate and fill prescription) enabling a patient to make an educated cost-based decision on where to fill a prescription* § No additional steps needed for the prescriber, fully integrated into current pres
Slide 44: vitaCare Prescription Services End to End Process
vitaCare Prescription Services End to End Process 1 Sales message integration 5 2 vitaCare receives the script, Data Analytics for Commercial proprietary software details cost Optimization efficiencies and solves payor hurdles 4 3 Customizes prescription fulfillment / adherence program Omni-channel
Slide 45: Simple Sales Messaging Integration
1 Simple Sales Messaging Integration § vitaCare ensures a seamless product and pharmacy experience for the patient and doctor § Sales training is focused not only on the product, but also how patient access and experience is improved through vitaCare § No additional cost and no additional paperwork
Slide 46: vitaCare Prescription Services End to End Process
vitaCare Prescription Services End to End Process 1 Sales message integration 5 2 vitaCare receives the script, Data Analytics for Commercial proprietary software details cost Optimization efficiencies and solves payor hurdles 4 3 Customizes prescription fulfillment / adherence program Omni-channel
Slide 47: vitaCare Receives Script from Doctor
2 vitaCare Receives Script from Doctor § vitaCare test adjudicates prescription to check insurance coverage and gather all usable information § Algorithm triages script through various endpoints and provides output detailing the most cost-efficient retail option for the patient to obtain the prescri
Slide 48: vitaCare Prescription Services End to End Process
vitaCare Prescription Services End to End Process 1 Sales message integration 5 2 vitaCare receives the script, Data Analytics for Commercial proprietary software details cost Optimization efficiencies and solves payor hurdles 4 3 Customizes prescription fulfillment / adherence program Omni-channel
Slide 49: Omni-Channel Patient Outreach
3 Omni-Channel Patient Outreach § vitaCare connects with patient via phone text or email § Reviews cost and coverage details with patient, including retail and mail order pharmacy fulfillment options § Enrolls patient in manufacturer’s affordability program if applicable § Ensures patient visibility
Slide 50: vitaCare Prescription Services End to End Process
vitaCare Prescription Services End to End Process 1 Sales message integration 5 2 vitaCare receives the script, Data Analytics for Commercial proprietary software details cost Optimization efficiencies and solves payor hurdles 4 3 Customizes prescription fulfillment / adherence program Omni-channel
Slide 51: Transfer to pharmacy of patient choice for fulfillment
4 Transfer to pharmacy of patient choice for fulfillment § Transfer clean, pharmacist verified prescription to the patient’s pharmacy of choice § Any retail pharmacy § Home delivery § Proprietary CRM software customizes script renewal reminders and future communication set up per patient’s preferenc
Slide 52: vitaCare Prescription Services End to End Process
vitaCare Prescription Services End to End Process 1 Sales message integration 5 2 vitaCare receives the script, Data Analytics for Commercial proprietary software details cost Optimization efficiencies and solves payor hurdles 4 3 Customizes prescription fulfillment / adherence program Omni-channel
Slide 53: Real-Time Data and Analytics Inform Sales Platform
5 Real-Time Data and Analytics Inform Sales Platform § De-identified patient data collected by software populates the sales platform in real-time with customized dashboards § Maximizes the effectiveness of Sales Reps § Deliver the right message to the right HCP at the right time § Proprietary CRM so
Slide 54: vitaCare Benefits All Healthcare Constituents
vitaCare Benefits All Healthcare Constituents Patient Benefits Manufacturer Benefits § Price transparency and affordability § Ability to manage business at the transaction level § Pharmacy services delivered omni-channel § Improve visibility on prescription fill rates § Modernized consumer experienc
TherapeuticsMD — Investor Presentation (September 2020) on 6ix